Avalo Therapeutics (AVTX) Long-Term Debt Repayments (2015 - 2019)

Avalo Therapeutics (AVTX) posted Long-Term Debt Repayments of $183114.0 for Q4 2019, up 652.26% on a QoQ basis from $24342.0 in Q3 2019.

Avalo Therapeutics (AVTX) Long-Term Debt Repayments (2015 - 2019) Analysis & Trends

Avalo Therapeutics' Long-Term Debt Repayments history runs 4 years deep, the most recent figure standing at $183114.0 for Q4 2019.

Quarterly Long-Term Debt Repayments changed N/A year-over-year to $183114.0 in Q4 2019, while the trailing twelve-month figure through Sep 2020 was $183114.0 (up 150.75% YoY) and the FY2019 annual result came in at $256140.0, changed N/A from the prior year.
Long-Term Debt Repayments was $183114.0 for Q4 2019 at Avalo Therapeutics, up from $24342.0 in the prior quarter.
Across five years, Long-Term Debt Repayments topped out at $892721.0 in Q2 2017 and bottomed at $24342.0 in Q1 2019.
A 4-year average of $577169.7 and a median of $787946.0 in 2015 frame the typical range for Long-Term Debt Repayments.
Peak annual rise in Long-Term Debt Repayments reached 8.99% in 2017, while the deepest fall reached 27.48% in 2017.
Avalo Therapeutics' Long-Term Debt Repayments stood at $787946.0 in 2015, then increased by 8.48% to $854732.0 in 2016, then declined by 29.03% to $606610.0 in 2017, then tumbled by 69.81% to $183114.0 in 2019.
Business Quant data shows AVTX's Long-Term Debt Repayments at $183114.0 in Q4 2019, $24342.0 in Q3 2019, and $24342.0 in Q2 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Repayments (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	7.64 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Avalo Therapeutics	1.04 Mn	1.04 Mn	-	-

Download Data